Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282507 | 1.00 | — | — | |
| SCHEMBL11046561 | 1.00 | LMNA (0.30) | LMNA | |
| Hydrochloric Acid SCHEMBL25253221 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL31152128 | 0.84 | — | — | |
| Dimethylamine SCHEMBL14890938 | 0.79 | — | — | |
| SCHEMBL25357530 | 0.74 | — | — | |
| SCHEMBL23452139 | 0.71 | FUCA1 (0.47) | LMNA | |
| SCHEMBL11048718 | 0.71 | FUCA1 (0.39) | — | |
| SCHEMBL23452135 | 0.71 | FUCA1 (0.47) | LMNA | |
| SCHEMBL18330744 | 0.71 | FUCA1 (0.39) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2829555-B1 | METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS INC (JP) | 2018-05-16 | — | — | EP | claimed |
| US-9315602-B2 | Method for producing olefin polymer | MITSUI CHEMICALS, INC. (JP) | 2016-04-19 | — | — | US | claimed |
| US-20260137795-A1 | EXATECAN IMMUNOCONJUGATES | IMMUNOME INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026103694-A1 | HDAC INHIBITOR, AND PREPARATION AND USE THEREOF | 赛岚(杭州)生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4655006-A2 | EXATECAN IMMUNOCONJUGATES | Immunome, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4642778-A1 | LSD1 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2020190791-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | FORMA THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-3019460-B1 | SELECTIVE TRANSFER HYDROGENATION OF CITRAL OR ETHYL CITRAL | DSM IP ASSETS BV (NL) | 2019-01-30 | — | — | EP | disclosed |
| EP-2829555-B1 | METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS INC (JP) | 2018-05-16 | — | — | EP | disclosed |
| WO-2017125358-A1 | METHOD FOR THE HOMOGENEOUSLY CATALYZED PRODUCTION OF MONO-N-SUBSTITUTED PIPERAZINES | BASF SE (DE) | 2017-07-27 | — | — | WO | disclosed |
| CN-103781937-B | Filmogen, the diaphragm seal using the filmogen, and application thereof | 东曹株式会社 | 2017-05-31 | — | — | CN | disclosed |
| US-9315602-B2 | Method for producing olefin polymer | MITSUI CHEMICALS, INC. (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20150045523-A1 | METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS, INC. (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2829555-A1 | METHOD FOR PRODUCING OLEFIN POLYMER | Mitsui Chemicals, Inc. (JP) | 2015-01-28 | — | — | EP | disclosed |
| WO-2001048037-A1 | MIXED METAL ALKOXIDE AND CYCLOALKADIENYL CATALYSTS FOR THE PRODUCTION OF POLYOLEFINS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | LMNA 76/4885 |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | NRAS, KRAS, HRAS | LMNA 3059/4885 |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | LMNA 2530/4885 |
| US-20260137795-A1 | EXATECAN IMMUNOCONJUGATES | ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDC1 | LMNA 1441/4885 |
| US-12479857-B2 | Bax inhibitors and uses thereof | BAX, TMBIM6, BCL2 | LMNA 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.